Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.40 |
| ▸ | CCR5 | P51681 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | PDE4A | P27815 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14432821 | 0.87 | HDAC1 (0.44) | CHEK1HDAC1STAT3 | |
| SCHEMBL14432804 | 0.86 | CYP1A2 (0.43) | TP53CHEK1CCR5CYP1A2 | |
| SCHEMBL14432776 | 0.85 | TP53 (0.47) | TP53CCR5CYP1A2PDE4B | |
| SCHEMBL14432791 | 0.84 | MEN1 (0.40) | CHEK1CCR5CYP1A2 | |
| SCHEMBL14432488 | 0.83 | NAMPT (0.40) | CCR5CYP1A2STAT3 | |
| SCHEMBL14432801 | 0.82 | CYP1A2 (0.41) | TP53CHEK1CCR5CYP1A2STAT3 | |
| SCHEMBL14432873 | 0.82 | PPARG (0.41) | TP53PPARGCHEK1CCR5CYP1A2 | |
| SCHEMBL5232381 | 0.81 | CCR5 (0.40) | TP53CHEK1CCR5CYP1A2HDAC1 | |
| SCHEMBL5228484 | 0.81 | TP53 (0.44) | TP53CCR5 | |
| SCHEMBL14432787 | 0.81 | PPARG (0.48) | TP53PPARGCHEK1CCR5CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581528-B1 | PIPERIDINYL-THIAZOLE CARBOXYLIC ACID DERIVATIVES AS ANGIOGENESIS INHIBITORS | METRIS THERAPEUTICS LTD (GB) | 2007-08-01 | — | — | EP | claimed |
| US-20060135501-A1 | Piperidinyl-thiazole carboxylic acid derivatives as angiogenesis inhibitors | DSPI LIMITED (GB) | 2006-06-22 | — | — | US | claimed |
| EP-1581528-B1 | PIPERIDINYL-THIAZOLE CARBOXYLIC ACID DERIVATIVES AS ANGIOGENESIS INHIBITORS | METRIS THERAPEUTICS LTD (GB) | 2007-08-01 | — | — | EP | disclosed |
| US-20060135501-A1 | Piperidinyl-thiazole carboxylic acid derivatives as angiogenesis inhibitors | DSPI LIMITED (GB) | 2006-06-22 | — | — | US | disclosed |
| EP-1581528-A1 | PIPERIDINYL-THIAZOLE CARBOXYLIC ACID DERIVATIVES AS ANGIOGENESIS INHIBITORS | Metris Therapeutics Limited (GB) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004058750-A1 | PIPERIDINYL-THIAZOLE CARBOXYLIC ACID DERIVATIVES AS ANGIOGENESIS INHIBITORS | METRIS THERAPEUTICS LIMITED (GB) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058751-A1 | PIPERIDINYL-THIAZOLE CARBOXAMIDE DERIVATIVES FOR ALTERING VASCULAR TONE | METRIS THERAPEUTICS LIMITED (GB) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135501-A1 | Piperidinyl-thiazole carboxylic acid derivatives as angiogenesis inhibitors | PGF, FLT1, VEGFA | TP53 2807/4885PPARG 75/4885CHEK1 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.